ES2372442T3 - Seprasa como marcador para cáncer. - Google Patents

Seprasa como marcador para cáncer. Download PDF

Info

Publication number
ES2372442T3
ES2372442T3 ES08859952T ES08859952T ES2372442T3 ES 2372442 T3 ES2372442 T3 ES 2372442T3 ES 08859952 T ES08859952 T ES 08859952T ES 08859952 T ES08859952 T ES 08859952T ES 2372442 T3 ES2372442 T3 ES 2372442T3
Authority
ES
Spain
Prior art keywords
cancer
seprase
markers
marker
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08859952T
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Rollinger
Johann Karl
Jarema Peter Kochan
Markus Roessler
Michael Tacke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07023897A external-priority patent/EP2071337A1/en
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2372442T3 publication Critical patent/ES2372442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/5752—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • G01N33/57535—
    • G01N33/57557—
    • G01N33/57565—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES08859952T 2007-12-10 2008-12-08 Seprasa como marcador para cáncer. Active ES2372442T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07023897 2007-12-10
EP07023897A EP2071337A1 (en) 2007-12-10 2007-12-10 Seprase as a marker for cancer
EP08015310 2008-08-29
EP08015310 2008-08-29

Publications (1)

Publication Number Publication Date
ES2372442T3 true ES2372442T3 (es) 2012-01-19

Family

ID=40373548

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08859952T Active ES2372442T3 (es) 2007-12-10 2008-12-08 Seprasa como marcador para cáncer.

Country Status (14)

Country Link
US (1) US8980573B2 (enExample)
EP (1) EP2223115B1 (enExample)
JP (1) JP5563988B2 (enExample)
KR (1) KR101202220B1 (enExample)
CN (1) CN101896818B (enExample)
AT (1) ATE524740T1 (enExample)
AU (1) AU2008335855B2 (enExample)
BR (1) BRPI0820793A2 (enExample)
CA (1) CA2706115A1 (enExample)
DK (1) DK2223115T3 (enExample)
ES (1) ES2372442T3 (enExample)
MX (1) MX2010004671A (enExample)
PL (1) PL2223115T3 (enExample)
WO (1) WO2009074275A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
ES2408964T3 (es) * 2008-07-03 2013-06-24 F. Hoffmann-La Roche Ag ASC como marcador del cáncer de pulmón
NZ600828A (en) 2009-12-20 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2585184T3 (es) * 2010-02-05 2016-10-04 Astute Medical, Inc. Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
US20130225442A1 (en) * 2010-10-20 2013-08-29 Rush University Medical Center Lung Cancer Tests
CA2826820A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Asc as marker for chronic obstructive pulmonary disease (copd)
CN103415772A (zh) * 2011-03-11 2013-11-27 霍夫曼-拉罗奇有限公司 表面表达蛋白酶作为慢性阻塞性肺病（copd）的标志物
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
US20140038838A1 (en) 2012-06-27 2014-02-06 Niven Rajin Narain Use of markers in the diagnosis and treatment of prostate cancer
CA2891028C (en) 2012-11-09 2017-02-07 F. Hoffmann-La Roche Ag In vitro capture and analysis of circulating tumor cells
SG11201504241QA (en) * 2012-11-30 2015-06-29 Applied Proteomics Inc Method for evaluation of presence of or risk of colon tumors
US9360488B2 (en) 2013-01-17 2016-06-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
EP3080299B1 (en) 2013-12-09 2020-09-30 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
PL230661B1 (pl) * 2014-01-29 2018-11-30 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc
EP2916134B1 (en) * 2014-03-05 2017-08-16 Roche Diagnostics GmbH Use of Seprase for differential diagnosis of acute dyspnea
CA2970143A1 (en) 2014-12-08 2016-06-16 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3029926C (en) * 2016-07-25 2023-01-03 Shizuoka Prefecture Diagnostic biomarker for extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
JP7134502B2 (ja) * 2017-09-05 2022-09-12 オンコタグ ダイアグノスティクス シーオー．， エルティーディー． メチオニルｔＲＮＡ合成酵素を利用した膵臓癌の診断方法及びこれを利用した膵臓癌の診断キット
CN112540176B (zh) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
WO2005043121A2 (en) 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
WO2007001420A2 (en) * 2004-10-22 2007-01-04 Genencor International, Inc. Isolating human antibodies
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
BRPI0620027A2 (pt) * 2005-12-19 2011-10-25 Tufts College inibidores da protease soft e formas pró-soft

Also Published As

Publication number Publication date
EP2223115B1 (en) 2011-09-14
PL2223115T3 (pl) 2012-02-29
BRPI0820793A2 (pt) 2015-06-16
AU2008335855A1 (en) 2009-06-18
ATE524740T1 (de) 2011-09-15
MX2010004671A (es) 2010-05-27
DK2223115T3 (da) 2011-12-12
US20100240081A1 (en) 2010-09-23
CN101896818A (zh) 2010-11-24
US8980573B2 (en) 2015-03-17
WO2009074275A1 (en) 2009-06-18
EP2223115A1 (en) 2010-09-01
KR101202220B1 (ko) 2012-11-16
CN101896818B (zh) 2016-01-20
JP2011506941A (ja) 2011-03-03
JP5563988B2 (ja) 2014-07-30
HK1150884A1 (zh) 2012-01-13
AU2008335855B2 (en) 2012-08-30
CA2706115A1 (en) 2009-06-18
KR20100091212A (ko) 2010-08-18

Similar Documents

Publication Publication Date Title
ES2372442T3 (es) Seprasa como marcador para cáncer.
ES2527649T3 (es) Panel de marcadores para el cáncer colorrectal
CA2760735C (en) Use of dppiv/seprase as a marker for cancer
US10815517B2 (en) Use of DPPIV/seprase as a marker for cancer
ES2434017T3 (es) Utilización del s-ErbB-3 como marcador de cáncer
CN101641599A (zh) 作为肺癌标志物的apex
EP2071337A1 (en) Seprase as a marker for cancer
ES2493070T3 (es) Flap endonucleasa-1 como marcador para el cáncer
ES2408964T3 (es) ASC como marcador del cáncer de pulmón
CN102439455B (zh) 作为肺癌标志物的cybp
HK1150884B (en) Seprase as a marker for cancer
HK1169168B (en) Use of dppiv/seprase as a marker for cancer
HK1165204B (en) Cybp as a marker of lung cancer
HK1151093A (en) Marker panel for colorectal cancer